SLDB: Solid Biosciences Inc.
Performance
Watchlist
Select an item
Summary
SLDB at a glance
SLDB returned +72.91% over the past year and -27.58% a year over five years. Its worst drop in that year was -50.99%, smaller than 22% of stocks on Redstone, and its Sharpe ratio of 1.05 beats 77% of stocks on Redstone. It pays no dividends.
Current Drawdown
-37.04%
Rolling Volatility
87.75%
Metrics
Risk Indicators
Profile
About SLDB
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $753M
- Listed
- Jan 2018
- Employees
- 121
- Headquarters
- Charlestown, MA
- Website
- solidbio.com
Comparisons